...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Have a great Sunday, especially those of you like me that are celebrating Orthodox Easter ... As well as those of you who are also like me and mourning another Maple Leafs Game 7 exit ... Ugggh!

Sincerely,

George et al

Message: Re: Article on Zenith....all financings in USD...expect Nasdaq IMHO
Reply New Message
Back To Forum List View
Article on Zenith....all financings in USD...expect Nasdaq IMHO
5
bfw
May 18, 2016 07:57AM

Nice find BFW. I will add it to the link library. A lot of good info in there. My favorite quote is:

"Competitor molecules "hit everything," McCaffrey explained. "We have drugs that are very good that hit everything, as well, but we also have drugs in the platform that can be specific for any one of the 12 domains.""

That is good to hear. My interpretation of this comment is that they have compounds that are not only specific to the first or the second bromodomain, but they can also target the first or the second bromodomain in a particular BET protein (such as BRD2, BRD3, BRD4, BRDT) or a subset of BRDs. Very exciting. This was the biggest criticism that I heard of the therapeutic potential of BET inhibitors at the Epigenetics: Cancer and Beyond NYAS webcast. So although Zenith is starting with a pan-inhibitor that will hit both bromodomains in most if not all BET proteins, they must have a lot in their pre-clinical pipeline.

BearDownAZ

9 Recommendations
Re: Article on Zenith....all financings in USD...expect Nasdaq IMHO
4
Hartland
May 18, 2016 11:43AM
Re: Article on Zenith....all financings in USD...expect Nasdaq IMHO
2
Hartland
May 18, 2016 12:16PM
Re: Article on Zenith....all financings in USD...expect Nasdaq IMHO
3
KayakerBC
May 18, 2016 12:44PM
$1/share
3
fouremm
May 23, 2016 02:59PM
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply